Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | CLL outcomes after CD19 CAR-T with ibrutinib

Jordan Gauthier • 30 Mar 2020
Chronic Lymphocytic Leukemia Leukemia Ibrutinib
TRANSCEND-NHL-001

Jordan Gauthier, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discussed the clinical outcomes of patients with chronic lymphocytic leukemia (CLL) with relapsed or refractory disease after CD19-specific CAR-T therapy used concurrently with ibrutinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jordan Gauthier

Relationship between IL-15 serum concentrations & CD19 CAR T-cell therapy 3:40
Relationship between IL-15 serum concentrations & CD19 CAR T-cell therapy
Jordan Gauthier • 28 Jan 2021
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies 3:23
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies
Jordan Gauthier • 28 Jan 2021
IACH webinar: continuing the CAR-T discussion amid COVID-19 1:46
IACH webinar: continuing the CAR-T discussion amid COVID-19
Jordan Gauthier • 30 Mar 2020
Repeat infusions of CD19 CAR-T 3:06
Repeat infusions of CD19 CAR-T
Jordan Gauthier • 30 Mar 2020

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals